<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01015651</url>
  </required_header>
  <id_info>
    <org_study_id>0823</org_study_id>
    <secondary_id>2008-A01602-53</secondary_id>
    <nct_id>NCT01015651</nct_id>
  </id_info>
  <brief_title>Assessment of the Nociception During Lumbar Surgery</brief_title>
  <acronym>CARDEAN-2</acronym>
  <official_title>Assessment of the Nociception During Lumbar Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Grenoble</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to assess the accuracy of a new paradigm in measuring the level of
      nociception during lumbar surgery. The paradigm is based the measurement of the baroreflex in
      response to noxious stimuli in anesthetized patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study aims at exploring the changes in the baroreflex induced by 3 noxious stimulation in
      anesthetized patients: tracheal intubation, tetanic stimulus, and surgical incision. Patients
      are randomly assigned to one of 2 groups: remifentanil-2 or remifentanil-4, corresponding to
      the target effect site concentration of this drug delivered through a TCI system. Other drugs
      included propofol and cisatracurium.

      The paradigm exploring the baroreflex collects information continuously recorded of the RR
      intervals and the changes in systolic arterial pressure, before and during noxious stimuli.
      The hypothesis is that this paradigm explores nociception as the group with smaller doses in
      remifentanil will have more cardiovascular reactions in response to noxious stimuli.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>changes in the baroreflex in response to noxious stimuli</measure>
    <time_frame>intraoperative</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>perioperative requirements in anesthetic agents.</measure>
    <time_frame>intraoperative</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Lumbar Surgery</condition>
  <arm_group>
    <arm_group_label>remifentanil-2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 2 ng/ml.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>remifentanil-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>In this group, patients are receiving a continuous i.v. infusion of remifentanil according to a target effect site concentration of 4 ng/ml.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.</description>
    <arm_group_label>remifentanil-2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>remifentanil</intervention_name>
    <description>anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.</description>
    <arm_group_label>remifentanil-4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ASA classification I-II

          -  undergoing lumbar surgery for discal hernia

          -  body mass index &lt;30 kg/m2

        Exclusion Criteria:

          -  ASA classification III-IV

          -  cardiac history that precludes RR recording : atrial fibrillation, arterial
             hypertension, active cardiac pacing, chronic treatment with beta-blockers,
             alpha-blockers, calcium-blockers and angiotensin receptors inhibitors

          -  diabetes

          -  regular intake of cocaine, alcohol

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Francois PAYEN, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Grenoble</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Grenoble</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2009</study_first_submitted>
  <study_first_submitted_qc>November 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 18, 2009</study_first_posted>
  <last_update_submitted>April 6, 2010</last_update_submitted>
  <last_update_submitted_qc>April 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 7, 2010</last_update_posted>
  <responsible_party>
    <name_title>Jean-Francois PAYEN</name_title>
    <organization>Anesthesia and Intensive Care, University Hospital, Grenoble</organization>
  </responsible_party>
  <keyword>nociception, intraoperative, baroreflex</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Remifentanil</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

